4D Molecular Therapeutics Inc. (FDMT): Price and Financial Metrics
GET POWR RATINGS... FREE!
FDMT POWR Grades
- FDMT scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.55% of US stocks.
- The strongest trend for FDMT is in Growth, which has been heading down over the past 179 days.
- FDMT's current lowest rank is in the Quality metric (where it is better than 9.74% of US stocks).
FDMT Stock Summary
- 4D Molecular Therapeutics Inc's stock had its IPO on December 11, 2020, making it an older stock than merely 1.54% of US equities in our set.
- FDMT's price/sales ratio is 29.22; that's higher than the P/S ratio of 94.53% of US stocks.
- FDMT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 7.91% of US stocks.
- If you're looking for stocks that are quantitatively similar to 4D Molecular Therapeutics Inc, a group of peers worth examining would be SLDB, RARE, ONCT, RGNX, and SRRK.
- To check out 4D Molecular Therapeutics Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001650648.
FDMT Valuation Summary
- In comparison to the median Healthcare stock, FDMT's price/earnings ratio is 139.73% lower, now standing at -14.5.
- FDMT's EV/EBIT ratio has moved up 7.6 over the prior 38 weeks.
- FDMT's price/sales ratio has moved down 77.6 over the prior 38 weeks.
Below are key valuation metrics over time for FDMT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FDMT | 2021-08-31 | 60.6 | 3.4 | -14.5 | -10.2 |
| FDMT | 2021-08-30 | 60.2 | 3.4 | -14.4 | -10.1 |
| FDMT | 2021-08-27 | 63.0 | 3.6 | -15.1 | -10.8 |
| FDMT | 2021-08-26 | 61.9 | 3.5 | -14.9 | -10.6 |
| FDMT | 2021-08-25 | 61.7 | 3.5 | -14.8 | -10.5 |
| FDMT | 2021-08-24 | 59.7 | 3.4 | -14.3 | -10.0 |
FDMT Price Target
For more insight on analysts targets of FDMT, see our FDMT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $50.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
FDMT Stock Price Chart Interactive Chart >
FDMT Price/Volume Stats
| Current price | $7.64 | 52-week high | $36.14 |
| Prev. close | $7.44 | 52-week low | $6.92 |
| Day low | $6.99 | Volume | 188,300 |
| Day high | $7.74 | Avg. volume | 213,193 |
| 50-day MA | $12.14 | Dividend yield | N/A |
| 200-day MA | $20.35 | Market Cap | 246.77M |
4D Molecular Therapeutics Inc. (FDMT) Company Bio
4D Molecular Therapeutics is a biotechnology company. The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Latest FDMT News From Around the Web
Below are the latest news stories about 4D Molecular Therapeutics Inc that investors may wish to consider to help them evaluate FDMT as an investment opportunity.
4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of DirectorsEMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies announced that Professor David Schaffer, Ph.D. has resigned as a director of 4D Molecular Therapeutics. Professor Schaffer’s transition coincides with the evolution of 4DMT into a clinical-stage gene therapy company with five products in clinical development and plans to develop pre-commercial |
4D Molecular Therapeutics (FDMT) WORLDSymposium 2022 - 4D-310 Updated Interim Clinical Data - SlideshowNo summary available. |
4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceEMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th . Details of the fireside chat are as follows: |
4D Molecular Shares Updated Data From Fabry Disease Trial4D Molecular Therapeutics Inc (NASDAQ: FDMT ) has … Full story available on Benzinga.com |
4D Molecular Therapeutics reports phase 1/2 trial interim data of 4D-310 in Fabry disease4D Molecular Therapeutics (FDMT) reported updated interim data from the ongoing phase 1/2 trial of 4D-310 in patients with Fabry disease.Following 4D-310 infusion, mean serum AGA |
FDMT Price Returns
| 1-mo | -37.68% |
| 3-mo | -46.54% |
| 6-mo | -64.33% |
| 1-year | -71.23% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -65.18% |
| 2021 | -47.07% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...